| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 17.35 | 4.3% |
| Total Income | 17.66 | 4.6% |
| Expenditure | 15.15 | 2.9% |
| PBT | 2.51 | 14.0% |
| Net Profit | 1.90 | 17.3% |
| OPM | 10.63% | 1.51pp |
| NPM | 10.75% | 1.65pp |
| EPS | 1.62 | 17.4% |
Sanjivani Paranteral Ltd Reports 16% YoY Growth in Total Income and 15% YoY Rise in PAT for Q3 FY25
11 Feb 2025 · 11 Feb 2025, 01:17 am
Summary
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, has reported a robust performance for the quarter ended 31 December 2024. The company's total income stood at INR 173.5 million, marking a 16% YoY growth, while the Profit After Tax (PAT) rose by 15% YoY to INR 19.0 million. The growth was driven by improved profitability and strategic cost management.
Key Highlights
- 1
Total income stood at INR 173.5 million, marking a 16% YoY growth
- 2
Profit After Tax (PAT) rose by 15% YoY to INR 19.0 million
- 3
Segment-wise, Injectables revenue grew 34.8% YoY to INR 129.2 million, Oral revenue grew 1.4% YoY to INR 34.1 million, and Nutraceuticals revenue grew 493.3% YoY to INR 10.2 million
- 4
Exports (incl. Exports incentives) constitute 84.9% of total revenue while domestic constitutes 15.1%
- 5
Core markets of CIS, Latin America, Middle East & Africa and Southeast Asia accounted for 84.9% to INR 147 million
Management Comments
Mr. Ashwani Khemka
We are pleased to report a steady performance in Q3 FY25, reflecting our continued focus on operational efficiency and sustainable growth. Total income stood at %173.5 million, marking a 16% YoY growth, while our PAT rose by 15% YoY to 19.0 million, driven by improved profitability and strategic cost management. Looking ahead, we remain focused on scaling our operations, enhancing product innovation, and expanding market reach. With a robust pipeline and operational efficiencies in place, we are confident in sustaining growth momentum and driving long-term value for our shareholders.
Informational and educational content only. Not investment advice.